Editas Medicine Inc. (NASDAQ:EDIT) Director Kevin Bitterman sold 21,480 shares of the firm’s stock in a transaction that occurred on Wednesday, November 23rd. The stock was sold at an average price of $15.71, for a total transaction of $337,450.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Kevin Bitterman also recently made the following trade(s): On Tuesday, November 15th, Kevin Bitterman sold 88,900 shares of Editas Medicine stock. The stock was sold at an average price of $16.96, for a total transaction of $1,507,744.00.
Shares of Editas Medicine Inc. (NASDAQ:EDIT) traded down 1.70% during trading on Monday, reaching $15.03. 274,006 shares of the company’s stock traded hands. Editas Medicine Inc. has a one year low of $12.43 and a one year high of $43.99. The stock’s market cap is $535.58 million. The company has a 50 day moving average price of $14.51 and a 200-day moving average price of $21.70.
Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.59) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.05. The business earned $1 million during the quarter, compared to analyst estimates of $1 million. Editas Medicine had a negative net margin of 1,184.46% and a negative return on equity of 59.22%. The firm’s revenue was up 49.3% on a year-over-year basis. On average, equities research analysts expect that Editas Medicine Inc. will post ($2.49) EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the stock. Nationwide Fund Advisors bought a new position in Editas Medicine during the second quarter valued at about $115,000. BlackRock Group LTD bought a new position in Editas Medicine during the third quarter valued at about $117,000. BlackRock Advisors LLC increased its position in Editas Medicine by 11.2% in the third quarter. BlackRock Advisors LLC now owns 9,817 shares of the company’s stock valued at $132,000 after buying an additional 990 shares during the period. PARK CIRCLE Co bought a new position in Editas Medicine during the third quarter valued at about $135,000. Finally, Metropolitan Life Insurance Co. NY bought a new position in Editas Medicine during the second quarter valued at about $181,000. Hedge funds and other institutional investors own 60.89% of the company’s stock.
A number of equities analysts recently issued reports on the stock. Jefferies Group raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a report on Wednesday, August 10th. Zacks Investment Research downgraded shares of Editas Medicine from a “hold” rating to a “sell” rating in a report on Monday, August 15th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Editas Medicine has a consensus rating of “Buy” and a consensus target price of $30.75.
Editas Medicine Company Profile